^
Association details:
| Biomarker: | HGF elevation + VEGFA elevation |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | erlotinib (EGFR inhibitor) + sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial
Published date:
10/01/2016
Excerpt:
...plasma biomarkers were measured in 494 (69%) patients (sorafenib plus erlotinib, n = 243; sorafenib plus placebo, n = 251)...Treatment arm-independent analyses showed that elevated hepatocyte growth factor [HGF; HR, 1.687 (high vs. low expression); endpoint multiplicity adjusted (e-adj) P = 0.0001] and elevated plasma VEGFA (HR, 1.386; e-adj P = 0.0377) were significantly associated with poor overall survival (OS) in multivariate analyses...
DOI:
10.1158/1078-0432.CCR-15-2883
